Piper Sandler Maintains Overweight on Immunome, Lowers Price Target to $30
Benzinga Newsdesk 1 hour ago
Analyst RatingsNewsPrice Target
Piper Sandler analyst Biren Amin maintains Immunome (NASDAQ:IMNM) with a Overweight and lowers the price target from $33 to $30.
Piper Sandler analyst Biren Amin maintains Immunome (NASDAQ:IMNM) with a Overweight and lowers the price target from $33 to $30.